Evidence map›Paper›PMID 24966859›Full record

ReviewFrontiers in immunology2014

Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections.

Laura Grange, Etienne Simon-Loriere, Anavaj Sakuntabhai, Lionel Gresh, Richard Paul, Eva Harris

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 5 pooled it
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 5 syntheses or guidelines pooled it, 196 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Laura GrangeUnité de la Génétique Fonctionnelle des Maladies Infectieuses, Institut Pasteur , Paris , France ; URA3012, Centre National de la Recherche Scientifique , Paris , France.
Etienne Simon-LoriereUnité de la Génétique Fonctionnelle des Maladies Infectieuses, Institut Pasteur , Paris , France ; URA3012, Centre National de la Recherche Scientifique , Paris , France.
Anavaj SakuntabhaiUnité de la Génétique Fonctionnelle des Maladies Infectieuses, Institut Pasteur , Paris , France ; URA3012, Centre National de la Recherche Scientifique , Paris , France.
Lionel GreshSustainable Sciences Institute , Managua , Nicaragua.
Richard PaulUnité de la Génétique Fonctionnelle des Maladies Infectieuses, Institut Pasteur , Paris , France ; URA3012, Centre National de la Recherche Scientifique , Paris , France.
Eva HarrisDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California , Berkeley, CA , USA.
Institut Pasteur · FRCentre National de la Recherche Scientifique · FRSustainable Sciences Institute · USUniversity of California, Berkeley · US

Funding

Epidemiological, Clinical & Immunological Studies of Zika, dengue and chikungunyaR01AI099631 · NIAID · SUSTAINABLE SCIENCES INSTITUTE · PI BALMASEDA, ANGEL LAZARO · 2012 to 2021
$1.8M
NIAID NIH HHS R01 AI099631
6 · The paper itself

Abstract

Dengue is a major international public health concern, and the number of outbreaks has escalated greatly. Human migration and international trade and travel are constantly introducing new vectors and pathogens into novel geographic areas. Of particular interest is the extent to which dengue virus (DENV) infections are subclinical or inapparent. Not only may such infections contribute to the global spread of DENV by human migration, but also seroprevalence rates in naïve populations may be initially high despite minimal numbers of detectable clinical cases. As the probability of severe disease is increased in secondary infections, populations may thus be primed, with serious public health consequences following introduction of a new serotype. In addition, pre-existing immunity from inapparent infections may affect vaccine uptake, and the ratio of clinically apparent to inapparent infection could affect the interpretation of vaccine trials. We performed a literature search for inapparent DENV infections and provide an analytical review of their frequency and associated risk factors. Inapparent rates were highly variable, but "inapparent" was the major outcome of infection in all prospective studies. Differences in the epidemiological context and type of surveillance account for much of the variability in inapparent infection rates. However, one particular epidemiological pattern was shared by four longitudinal cohort studies: the rate of inapparent DENV infections was positively correlated with the incidence of disease the previous year, strongly supporting an important role for short-term heterotypic immunity in determining the outcome of infection. Primary and secondary infections were equally likely to be inapparent. Knowledge of the extent to which viruses from inapparent infections are transmissible to mosquitoes is urgently needed. Inapparent infections need to be considered for their impact on disease severity, transmission dynamics, and vaccine efficacy and uptake.

Indexed as

asymptomaticdengueinapparentinfectionsubclinical

Identifiers

PMID24966859
PMCPMC4052743
OpenAlexW2112514322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.